| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5d8635485bf8ebf2ab2ccdbbacf8007 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0658
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-027 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2016-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_210c35b6636709d9e671daafb4573398
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3dd0b9ea8dd0554067d1809e329216e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffd114baddd86c94cc3c57df7f067e7c |
| publicationDate |
2018-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018140562-A1 |
| titleOfInvention |
Muscular atrophy-inducing agent using hypometabolism-inducing substance t1am, and use thereof in treating muscular hypertrophy |
| abstract |
The present invention relates to: a muscular atrophy-inducing agent containing, as an active ingredient, a hypometabolism-inducing substance selected from the group consisting of 3-iodothyronamine (T1AM), [D-Ala2,D-Leu5] enkephalin (DADLE), 5′-adenosine monophosphate (5′-AMP), and hydrogen sulfide (H 2 S); a method for preparing a muscular atrophy study model comprising inducing muscular atrophy by administering the muscular atrophy-inducing agent; a study model prepared by the method; a screening method for a drug for preventing or treating muscular atrophy using the same; a composition for preventing or treating muscular hypertrophy; and a composition for facial muscle shrinkage. The muscular atrophy study model according to the present invention can provide a study model for an economic muscular atrophy study by using a hypometabolism-inducing substance which can be mass-produced, has an effect which may be usefully used by verification for screening of a drug for preventing or treating muscular atrophy, and can be usefully used as a compositions for preventing or treating muscular hypertrophy and a composition for facial muscle shrinkage through the muscular atrophy effect. |
| priorityDate |
2015-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |